Pharmacotherapy of intraocular pressure part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 17, 2009, Pages 2859-2870

  Costagliola, Ciro ^a   Dell'Omo, Roberto ^a   Romano, Mario R ^a   Rinaldi, Michele ^b   Zeppa, Lucia ^a   Parmeggiani, Francesco ^c  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Acetazolamide; Bimatoprost; Brinzolamide; Carbonic anhydrase inhibitors; Dorzolamide; Glaucoma; Latanoprost; Prostaglandin analogues; Prostamides; Travoprost

Indexed keywords

ACECLIDINE; ACETAZOLAMIDE; ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADRENALIN; APRACLONIDINE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CLONIDINE; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; PILOCARPINE; PROPRANOLOL DERIVATIVE; PROSTAGLANDIN DERIVATIVE; PROSTAMIDE DERIVATIVE; PROSTANOID; SULFONAMIDE; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

APLASTIC ANEMIA; AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; ASTHENIA; BITTER TASTE; BLOOD ANALYSIS; BLOOD PRESSURE; BLURRED VISION; BONE MARROW SUPPRESSION; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CYST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY EYE; EPIPHORA; EVENING DOSAGE; EYELASH; EYELID INFLAMMATION; FATIGUE; FOREIGN BODY REACTION; GLAUCOMA; HEADACHE; HEART RATE; HIRSUTISM; HUMAN; INFLAMMATION; INSECT STING; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRIS CYST; IRIS DISEASE; IRIS PIGMENTATION; KERATITIS; LEUKOPENIA; LIVER FUNCTION TEST; MALAISE; METABOLIC ACIDOSIS; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NONHUMAN; PANCYTOPENIA; PARESTHESIA; PATIENT COMPLIANCE; PIGMENTATION; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN PIGMENTATION; THROMBOCYTOPENIA; TRANSAMINATION; URINALYSIS; UROLITHIASIS; UVEITIS;

AMIDES; CARBONIC ANHYDRASE INHIBITORS; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS;

EID: 73149117367     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903300129     Document Type: Review

References (83)

1. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971;12:275-281
2. Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci 1980;19:256-266
3. Toris CB, Yablonski ME, Wang YL, Camras CB. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 1999;127:407-412
4. Alm A, Nilsson SF. Uveoscleral outflow - a review. Exp Eye Res 2009;88:760-768
5. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-189
6. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. Am J Ophthalmol 1954;37:13-15
7. Sirbat D. What should we think? Should diamox and pilocarpine continue to be prescribed? J Fr Ophtalmol 2007;30(Suppl 3):S72-3
8. Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G. Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm Biotechnol 1998;11:555-574
9. Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol 1997;42:137-151
10. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19:87-112
11. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308-313
12. Ormrod D, Mcclellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 2000;17:477-496
13. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836-837
14. Costagliola C, Campa C, Parmeggiani F, et al. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. Br J Clin Pharmacol 2007;63:376-379
15. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44(Suppl 2):S119-29
16. Silver LH. Clinical efficacy and safety of brinzolamide (azopt), a new topical carbonic anhydrase inhibitor for primary open angle glaucoma and ocular hypertension. Am J Ophthalmol 1998;126:400-408
17. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204-1212
18. Iester M. Brinzolamide. Expert Opin Pharmacother 2008;9:653-662
19. Croxtall JD, Scott LJ. Brinzolamide/ timolol: in open-angle glaucoma and ocular hypertension. Drugs Aging 2009;26:437-446
20. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
21. Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide-associated aplastic anaemia. J Intern Med 1990;228:627-632
22. Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol 2008;92:500-504
23. Lin JC, Samuel F, Katz LJ, et al. The effect of topical glaucoma medications evaluated by perimetry. Br J Ophthalmol 2003;87:792
24. Remky A, Weber A, Arend O, Sponsel WE. Topical dorzolamide increases pericentral visual function in age-related maculopathy: pilot study findings with short-wavelength automated perimetry. Acta Ophthalmol Scand 2005;83:154-160
25. Alm A, Nilsson SF. Uveoscleral outflow-a review. Exp Eye Res 2009;88:760-768
26. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008;115:790-795
27. + mobilization and MAP kinase activation. J Ocul Pharmacol Ther 2003;19:437-455
28. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-515
29. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003;44:715-721
30. Oh DJ, Martin JL, Williams AJ, et al. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2006;47:3887-3895
31. Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol 2003;14:65-69
32. Lindsey JD, To HD, Weinreb RN. Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1994;35:242-250
33. Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res 1988;47:761-769
34. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794-801
35. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001;108:25-30
36. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 2002;43:1475-1487
37. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(Suppl 1):S6-12
38. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41(Suppl 2): S105-10
39. Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 2003;20:597-630
40. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-1185
41. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-1752
42. Costagliola C, Del Prete A, Verolino M, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side-effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol 2002;240:379-386
43. Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2008;18:408-416
44. Susanna R, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002;47(Suppl 1):97-104
45. Krohn J, Hove VK. Iris cyst associated with topical administration of latanoprost. Am J Ophthalmol 1999;127:91-93
46. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53(Suppl 1):93-105
47. Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol 2002;133:393-1137
48. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-604
49. Beam G, Reardon G, Zimmerman TJ. Association between ocular herpes simplex virus and topical ocular hypotensive therapy. J Glaucoma 2004;13:361-364 (Pubitemid 39281575)
50. Reis R, dos Santos LC, Vila MP, Magacho L. Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study. Clin Ther 2004;26:2121-2127
51. Yan DB, Battista RA, Haidich AB, Konstas AG. Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma. Curr Med Res Opin 2008 [Epub ahead of print]
52. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-422
53. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007;6:45-52
54. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484
55. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 2008;53(Suppl 1):69-84
56. Konstas AG, Tsironi S, Vakalis AN, et al. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol 2009;87:71-76
57. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667-673
58. Honrubia F, García-Sánchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009;93:316-321
59. Camras CB. Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol 2002;133:732
60. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 2009;53:176-179
61. Woodward DF, Krauss AH, Wang JW, et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin- ethanolamides) in the feline iris. Br J Pharmacol 2007;150:342-352
62. Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009;158:104-145
63. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 2008;153:410-419
64. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (lumigan). Surv Ophthalmol 2001;45(Suppl 4):337-345
65. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19-24
66. Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023-1031
67. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45:353-360
68. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-121
69. Tappeiner C, Perren B, Iliev ME, et al. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - can bimatoprost cause enophthalmos? Klin Monatsbl Augenheilkd 2008;225:443-445
70. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/ Latanoprost Study Group. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 2004;49(Suppl 1):19-25
71. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-614
72. Parrish RK, Palmberg P, Sheu WP. XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
73. Von Weber A. Die Ursache des Glaukoms. Albr Graefes Arch Ophthalmol 1877;23:91-94
74. Hamburger C. Das starkete Mioticum. Ztschr Augenh 1926;60:109-110
75. Kreitmar H. Eine neue Klasse Cholinester. Naunyn Schmiedebergs Arch Exptl Path Pharmakol 1932;164:346-356
76. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. Am J Ophthalmol 1954;37:13-15
77. Mashkovskii Md, Zaitseva KA. On the pharmacology of 3-acetoxyquinuclidine (aceclidine). Farmakol Toksikol 1960;23:398-406
78. Kenigsberg PA. Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France. Eur J Ophthalmol 2007;17:521-527
79. Sit AJ, Asrani S. Effects of medications and surgery on intraocular pressure fluctuation. Surv Ophthalmol 2008;53(Suppl 1):45-55
80. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003;48(Suppl 1):17-20
81. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-2573
82. Coleman AL. Applying evidence-based medicine in ophthalmic practice. Am J Ophthalmol 2002;134:599-601
83. Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 2003;4:1775-1788